Featured StoryEditor's Pick
Latest Articles
Perimenopause, HRT, and What Actually Changed: How a Generation Was Steered Wrong About Hormone Therapy
For two decades after the 2002 Women's Health Initiative trial findings, hormone therapy was viewed as too dangerous for most women — even those with debilitating symptoms. The evidence has since been substantially reassessed, and the 2022 Menopause Society position statement, the 2024 NICE guideline update, and a series of re-analyses have brought HRT back to mainstream practice for symptomatic women under 60. Here is what the current evidence actually shows about perimenopause, what HRT does, and what the real risks are.
A Generation Caught in a Bad Information Loop
For about two decades after July 2002, the dominant message about menopausal hormone therapy was simple and badly misleading: it causes breast cancer and heart attacks; avoid it. The conclusion came from the initial reports of the Women's Health Initiative (WHI), a large randomized trial whose early findings — published with significant alarm — caused prescription rates of hormone therapy to drop by more than two-thirds within a few years. Doctors who had been comfortable prescribing it became reluctant. Women who had been taking it stopped, often abruptly. And a generation of women going through perimenopause and menopause in the 2000s and 2010s were systematically told the safest path was to "tough it out."
The evidence didn't stay where the 2002 reports left it. Subsequent re-analyses, longer follow-ups, and the realization that the original WHI cohort was not representative of the women who actually need hormone therapy have produced a substantially different picture. The 2022 Hormone Therapy Position Statement of The North American Menopause Society — endorsed by more than 20 international medical organizations — explicitly concluded that for most healthy symptomatic women under 60, or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks [1]. The UK's National Institute for Health and Care Excellence updated its menopause guideline in November 2024 along the same broad lines [2].
This is one of the larger course corrections in recent medical history, and many women, partners, and primary care physicians are still operating on the older information. Here is what the current evidence actually shows.
What Perimenopause Actually Is
Perimenopause is the transitional phase before menopause itself, typically lasting four to eight years, beginning most often in the early-to-mid 40s and ending when a woman has gone twelve consecutive months without a menstrual period. The defining biological event is the progressive decline and increasing erratic fluctuation of ovarian hormone production — estrogen and progesterone levels do not simply fall but oscillate, sometimes dramatically, before settling at the lower postmenopausal baseline.
The symptom picture is correspondingly broad. Vasomotor symptoms — hot flashes, night sweats — get the most attention, but they are far from the full list. A 2024 cohort study published in BJPsych Open of more than 2,000 perimenopausal and menopausal women found that psychological symptoms — low mood, anxiety, brain fog, poor concentration, memory complaints — were reported by the majority of respondents, often as the most disabling aspect of the transition, and were frequently misattributed to depression, ADHD, or stress when the underlying driver was hormonal [3]. Sleep disruption, joint pain, vaginal dryness, recurrent urinary tract infections, decreased libido, weight redistribution, and changes in hair and skin are all consistent components of the picture for many women.
The public narrative that menopause is mostly hot flashes is wrong, and that misframing has contributed to a lot of women — and their clinicians — failing to connect symptoms to their actual cause.
What the WHI Trial Actually Found, and What Got Lost
The 2002 WHI report was an interim analysis of a large randomized trial of combined estrogen-plus-progestin therapy. The headline finding was a statistically significant increase in invasive breast cancer in the treatment arm, alongside increases in cardiovascular events and stroke. The trial was halted early on safety grounds, and the news coverage was substantial.
What got lost in subsequent years is the context. The average age of women enrolled in the WHI was 63 — roughly a decade after the typical age of menopause onset. Many participants were not having significant menopause symptoms and were not the population that hormone therapy is principally intended for. The trial was designed to test whether hormone therapy could prevent chronic disease in older postmenopausal women, not whether it could safely manage symptoms in women going through the menopausal transition. Those are different clinical questions with different risk-benefit profiles. A 2023 reappraisal published in Maturitas argued that this distinction was inadequately communicated in the original press cycle, and that subsequent re-analyses of the WHI data — together with external evidence from observational studies and other trials — support what is now called the "timing hypothesis": hormone therapy initiated within ten years of menopause onset, or before age 60, has a substantially different risk profile than therapy initiated in women a decade or more past menopause [4].
The absolute risk increases also need to be sized to be meaningful. A 2019 worldwide individual-patient meta-analysis published in The Lancet pooled data from more than 100,000 women who developed breast cancer and analyzed type-specific and timing-specific risks of menopausal hormone therapy [5]. The analysis confirmed an elevated breast cancer risk with combined estrogen-progestogen therapy, but the absolute increase was modest — on the order of a few additional cases per 1,000 women per five years of use, varying with formulation and duration. Estrogen-only therapy (used in women who have had a hysterectomy) showed a smaller absolute increase. These numbers are real and should be discussed with women considering hormone therapy; they are not the catastrophic risk the 2002 coverage suggested for most users.
What the Current Guidelines Actually Say
The 2022 NAMS position statement is the most cited current US guidance. Its central conclusion: "Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture" [1]. The statement explicitly supports hormone therapy for most healthy symptomatic women under age 60, or within 10 years of menopause onset, and notes that the therapy does not need to be routinely discontinued at age 60 or 65 — continuation can be appropriate for persistent symptoms or osteoporosis prevention after individualized review of benefits and risks.
The November 2024 update to the UK NICE menopause guideline (NG23) is broadly consistent. It explicitly offers HRT for vasomotor symptoms associated with menopause, recommends discussion of benefits and risks tailored to the individual, supports vaginal estrogen for genitourinary symptoms (including in women with a history of breast cancer in many cases), and identifies menopause-specific cognitive behavioural therapy as an evidence-based option alongside or instead of HRT [2].
Both sets of guidelines emphasize three things that the older clinical practice often missed: that HRT formulation matters (transdermal estrogen carries lower thromboembolic risk than oral; micronized progesterone appears safer than synthetic progestins for some outcomes); that route of administration matters (transdermal versus oral changes the cardiovascular and clotting profile); and that the goal is symptom management calibrated to the individual, not a fixed-dose-for-fixed-duration regimen.
What HRT Treats Well, and What It Doesn't
What hormone therapy is genuinely effective for:
- **Vasomotor symptoms.** Hot flashes and night sweats — the most consistent, well-documented indication, with effect sizes substantially larger than any non-hormonal alternative [1].
- **Genitourinary syndrome of menopause.** Vaginal dryness, painful sex, recurrent urinary tract infections — these respond well to systemic or, for many women, low-dose local vaginal estrogen, which has minimal systemic absorption.
- **Bone loss and fracture prevention.** A well-established effect, with HRT recognized as an effective bone-preservation strategy in younger postmenopausal women at fracture risk.
- **Sleep disturbance secondary to vasomotor symptoms.** When night sweats are driving sleep fragmentation, HRT often resolves both.
- **Mood and cognitive symptoms during the menopausal transition.** Evidence here is growing but more nuanced: HRT can improve mood in perimenopausal women, particularly those with vasomotor symptoms, but it is not a first-line treatment for major depression in postmenopausal women [3].
What hormone therapy is not:
- **A general longevity intervention.** The original premise of preventing chronic disease in older women is not supported; HRT is a symptom-management therapy, not a "stay young" strategy.
- **Primary cardiovascular protection.** Earlier hopes that HRT would prevent heart disease in postmenopausal women were not borne out. The current understanding — the timing hypothesis — is that HRT initiated near menopause does not appear to increase cardiovascular risk and may have some benefit, but it is not prescribed for the purpose of preventing heart disease in any current guideline [4].
- **A substitute for evaluation of other conditions.** Many perimenopausal symptoms overlap with thyroid disease, depression, sleep apnea, and other conditions. Attributing every symptom in a 47-year-old to hormones is the mirror image of the older "tough it out" framing, and it can mean missing a different diagnosis.
The Honest Risk Conversation
The risks of HRT exist and need to be sized accurately. For combined estrogen-progestogen therapy, the principal risks are a modest increase in breast cancer (the Lancet 2019 meta-analysis quantified this carefully), a small increase in venous thromboembolism risk (largely with oral formulations; transdermal estrogen carries lower risk), and a small increase in stroke risk in older users [5]. For estrogen-only therapy, the breast cancer signal is smaller; thromboembolic risks are similar.
The size of these risks varies meaningfully with formulation, dose, route of administration, age at initiation, time since menopause, and individual factors including body mass index, smoking status, family history, and underlying cardiovascular risk. This is why current guidelines emphasize personalization and shared decision-making rather than a single "yes/no" answer [1][2].
For women with a personal history of estrogen-receptor-positive breast cancer, systemic HRT is generally avoided, though low-dose vaginal estrogen for genitourinary symptoms is increasingly used with breast cancer specialist input. For women with active liver disease, undiagnosed vaginal bleeding, recent thromboembolism, or active coronary disease, HRT is typically contraindicated.
A Practical Synthesis
Perimenopause and the years immediately following menopause are a period in which many women have legitimate, often disabling symptoms — and modern guidelines support HRT as an effective treatment for those symptoms in most women under 60 or within 10 years of menopause onset. The 2002 "HRT is dangerous" framing has not held up under closer examination; the 2022 NAMS position statement and the 2024 NICE guideline reflect the current evidence base.
If you are experiencing symptoms you suspect are perimenopausal — and particularly if the conversation with your primary care provider has been dismissive, or if you have been told you are "too young" for menopause symptoms in your early 40s — it is reasonable to seek a clinician with current menopause expertise. The Menopause Society (US) and the British Menopause Society both maintain directories of certified clinicians.
This article cannot substitute for a clinical conversation about your own circumstances. HRT is highly individualized — the right formulation, dose, and duration depend on your specific symptoms, medical history, and preferences. The point of this piece is narrower: that the prevailing public message about HRT has been substantially out of step with the current evidence for two decades, and that this gap has cost a generation of women effective treatment for genuine, evidence-recognized symptoms. The current guidance is not "everyone should take HRT" — it is "for most healthy symptomatic women under 60, HRT is a reasonable and effective treatment option that deserves a real conversation rather than reflexive avoidance."
If perimenopausal symptoms are affecting your daily life, talk to a healthcare professional with current menopause expertise. The conversation is one many women have been told for years not to have. It deserves to be had.
Further Reading
The 2022 Hormone Therapy Position Statement of The North American Menopause Society (Menopause, Vol 29, No 7, July 2022) — current US authoritative guidance on HRT, endorsed by 20+ international medical organizations
menopause.org
Menopause: identification and management (NICE Guideline NG23, November 2024 update) — current UK authoritative guidance on perimenopause and menopause management, including HRT, vaginal estrogen, and CBT recommendations
nice.org.uk
Reisel D., Crockett C., Glynne S., Kamal A., Newson L. — Prevalence of Cognitive and Mood-Related Symptoms in a Large Cohort of Perimenopausal and Menopausal Women (BJPsych Open, 2024) — cohort study quantifying psychological symptom prevalence during the menopausal transition
ncbi.nlm.nih.gov
Reappraising 21 years of the WHI study: Putting the findings in context for clinical practice (Maturitas, 2023) — peer-reviewed reappraisal of the WHI trial in light of subsequent evidence, formalizing the timing hypothesis
maturitas.org
Collaborative Group on Hormonal Factors in Breast Cancer — Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence (The Lancet, 2019) — worldwide individual-patient meta-analysis quantifying breast cancer risk by HRT type and timing
thelancet.com
📢 Advertisement — In-Article Ad